Asciminib
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Novartis PharmaceuticalsSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 81/ 100
Competitive context
34 Active assets in the Leukemia, Lymphoblastic, Acute, Philadelphia-Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib The University of Hong Kong | Phase 2 | BBB |
Cytosin-Arabinosid Novartis Pharmaceuticals | Phase 3 | BBB |
Blinatumomab Novartis Pharmaceuticals | Phase 3 | BBB |
METHOTREXATE Novartis Pharmaceuticals | Phase 3 | BB |
Imatinib The University of Hong Kong | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Asciminib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
60 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →